Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

In-Jin Jang

Showing results (21-30 of 292) with videos related to

Pageof 30
Sort By:
Translational and Clinical Pharmacology|February 15, 2020
A post hoc analysis of intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studiesInbum Chung, Jaeseong Oh, SeungHwan Lee, et al.
Translational and Clinical Pharmacology|February 15, 2020
Retraction and Republication: A post hoc analysis of intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studiesInbum Chung, Jaeseong Oh, SeungHwan Lee, et al.
Drug Design, Development and Therapy|October 30, 2020
Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male SubjectsInyoung Hwang, Yun Kim, Hyounggyoon Yoo, et al.
British Journal of Clinical Pharmacology|May 12, 2023
Pharmacokinetic and pharmacodynamic exploration of various combinations of tegoprazan immediate and delayed-release formulationsSooyoun Park, Eunsol Yang, Byungwook Kim, et al.
Investigational New Drugs|January 29, 2014
An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjectsKwang-Hee Shin, Kyoung Soo Lim, Howard Lee, et al.
Drug Design, Development and Therapy|May 5, 2016
The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartanNamyi Gu, Joo-Youn Cho, Kwang-Hee Shin, et al.
Translational and Clinical Pharmacology|February 26, 2020
Hydrochlorothiazide does not increase furosemide's effects in end-stage renal diseaseWooseong Huh, Ha-Young Oh, Jin Suk Han, et al.
Basic & Clinical Pharmacology & Toxicology|May 25, 2019
A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third-generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteersYoung Su Noh, Seonghae Yoon, Suk Ran Kim, et al.
Drug Design, Development and Therapy|September 15, 2025
Population Pharmacokinetic and Pharmacodynamic Modeling of Enteric-Coated Aspirin Capsule and Tablet Formulations in Healthy SubjectsJaeEun Koh, Juyoung Khwarg, Kyung-Sang Yu, et al.
Journal of Clinical Pharmacology|October 8, 2010
Population pharmacokinetic analysis and dosing regimen optimization of aprotinin in neonates and young infants undergoing cardiopulmonary bypassYou-Me Tae, Jae Gun Kwak, Bo-Hyung Kim, et al.
Pageof 30

Showing results (21-30 of 292) with videos related to

Sort By:
Pageof 30
Translational and Clinical Pharmacology|February 15, 2020
A post hoc analysis of intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studiesInbum Chung, Jaeseong Oh, SeungHwan Lee, et al.
Translational and Clinical Pharmacology|February 15, 2020
Retraction and Republication: A post hoc analysis of intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studiesInbum Chung, Jaeseong Oh, SeungHwan Lee, et al.
Drug Design, Development and Therapy|October 30, 2020
Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male SubjectsInyoung Hwang, Yun Kim, Hyounggyoon Yoo, et al.
British Journal of Clinical Pharmacology|May 12, 2023
Pharmacokinetic and pharmacodynamic exploration of various combinations of tegoprazan immediate and delayed-release formulationsSooyoun Park, Eunsol Yang, Byungwook Kim, et al.
Investigational New Drugs|January 29, 2014
An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjectsKwang-Hee Shin, Kyoung Soo Lim, Howard Lee, et al.
Drug Design, Development and Therapy|May 5, 2016
The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartanNamyi Gu, Joo-Youn Cho, Kwang-Hee Shin, et al.
Translational and Clinical Pharmacology|February 26, 2020
Hydrochlorothiazide does not increase furosemide's effects in end-stage renal diseaseWooseong Huh, Ha-Young Oh, Jin Suk Han, et al.
Basic & Clinical Pharmacology & Toxicology|May 25, 2019
A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third-generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteersYoung Su Noh, Seonghae Yoon, Suk Ran Kim, et al.
Drug Design, Development and Therapy|September 15, 2025
Population Pharmacokinetic and Pharmacodynamic Modeling of Enteric-Coated Aspirin Capsule and Tablet Formulations in Healthy SubjectsJaeEun Koh, Juyoung Khwarg, Kyung-Sang Yu, et al.
Journal of Clinical Pharmacology|October 8, 2010
Population pharmacokinetic analysis and dosing regimen optimization of aprotinin in neonates and young infants undergoing cardiopulmonary bypassYou-Me Tae, Jae Gun Kwak, Bo-Hyung Kim, et al.
Pageof 30